Clinical Trials in the UK / NCT05002127
Active, not recruiting
Phase 2/3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Investigational drug(s) / intervention(s)
Evorpacept (ALX148): IV Q2W
Trastuzumab: IV Q2W
Ramucirumab: IV Q2W
Paclitaxel: IV Days 1, 8, and 15 of a 28-day cycle
Study summary
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Eligibility
Inclusion Criteria:
* HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
* Adequate Bone Marrow Function.
* Adequate Renal \& Liver Function.
* Adequate Performance Status
Exclusion Criteria:
* Patients with known symptomatic central nervous system (CNS) metastases or leptomeningeal disease requiring steroids.
* Prior treatment with any anti-CD47 or anti-SIRPα agent.
* Prior treatment with ramucirumab.
Primary outcome measure(s)
- Phase 2 — Last randomized patient on study at least 16 weeks
Percentage of patients with objective response per RECIST 1.1 - Phase 3 — From the date of randomization to the date of death (due to any cause), up to 36 months postdose
Overall Survival
Trial sites (83)
| Facility | City | Region | Status |
|---|---|---|---|
| The Oncology Institute of Hope & Innovation | Anaheim | California | |
| University of California Los Angeles | Los Angeles | California | |
| Vanderbilt University Medical Center | Nashville | Tennessee | |
| NEXT Virginia | Fairfax | Virginia | |
| Fred Hutchinson Cancer Center | Seattle | Washington | |
| Icon Cancer Centre Southport | Southport | Queensland | |
| Monash Medical Centre | Clayton | Victoria | |
| Universitair Ziekenhuis Antwerpen | Antwerp | Belgium | |
| Universitair Ziekenhuis Leuven - Campus Gasthuisberg | Leuven | Belgium | |
| Centre Hospitalier Universitaire de Liège | Liège | Belgium | |
| Fakultní Nemocnice Hradec Králové | Hradec Králové | Czechia | |
| Fakultní Nemocnice Olomouc | Olomouc | Czechia | |
| Vseobecna Fakultni Nemocnice v Praze | Prague | Czechia | |
| Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz | Besançon | France | |
| Centre Hospitalier Universitaire de Bordeaux | Bordeaux | France | |
| Hôpital Morvan | Brest | France | |
| Centre Léon Bérard | Lyon | France | |
| Hôpital Privé Jean Mermoz | Lyon | France | |
| Institut Paoli-Calmettes | Marseille | France | |
| Hôpital Saint-Antoine | Paris | France | |
| Hôpital Trousseau | Paris | France | |
| Hôpital Rangueil | Toulouse | France | |
| Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi | Catania | Italy | |
| Azienda Ospedaliero - Universitaria Careggi | Florence | Italy | |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | |
| Policlinico Universitario Campus Bio-Medico | Roma | Italy | |
| Azienda Sanitaria Universitaria Friuli Centrale - P.O. Santa Maria della Misericordia | Udine | Italy | |
| National Cancer Center Hospital East | Chiba | Japan | |
| Kyushu Cancer Center | Fukuoka | Japan | |
| Gifu University Hospital | Gifu | Japan | |
| Japanese Red Cross Kumamoto Hospital | Kumamoto | Japan | |
| University Hospital Kyoto Prefectural University of Medicine | Kyoto | Japan | |
| Nagasaki University Hospital | Nagasaki | Japan | |
| Osaka Prefectural Hospital Organization - Osaka International Cancer Institute | Osaka | Japan | |
| Kindai University Hospital | Osaka | Japan | |
| Oita University Hospital - Hasama Campus | Ōita | Japan | |
| Saitama Cancer Center | Saitama | Japan | |
| Tohoku University Hospital | Sendai | Japan | |
| Shizuoka Cancer Center | Shizuoka | Japan | |
| National Cancer Center Hospital | Tokyo | Japan |
+ 43 more sites — see the full list on the official registry below.
On this site
📄 Herceptin (trastuzumab) drug profile →More ALX Oncology Inc. trials in the UK
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05002127 on ClinicalTrials.gov ↗ ← All trials in the UK